MedTrace Logo

CBT vs. ABM vs. for Social Anxiety

NCT01909193 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2016-02-23

No results posted yet for this study

Summary

Adults with Social Anxiety Disorder will be pseudo randomly assigned to either an individual cognitive behavior therapy, attention bias modification treatment (allocation ratio - 1.5:1).

Outcome measures will be social anxiety symptoms and severity as measured by gold standard questionnaires as well as diagnosis of social anxiety disorder derived from structured clinical interviews based on Diagnostic and Statistical Manual (DSM) IV criteria.

The investigators expect to find significant reduction in social anxiety symptoms in all of the groups, with the cognitive behavior therapy group showing greater reduction in symptoms than the other groups. Mechanisms of change in all of the groups will be examined via measures of cognitive biases, affect, and other common and specific factors.

Conditions

  • Social Phobia

Interventions

BEHAVIORAL

Attention Bias Modification (ABM)

Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.

BEHAVIORAL

Cognitive Behavior Therapy

CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions

Sponsors & Collaborators

  • Israel Science Foundation

    collaborator OTHER

  • Hebrew University of Jerusalem

    lead OTHER

Principal Investigators

  • Jonathan D Huppert, PhD · Hebrew University of Jerusalem

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2014-07-31
Completion
2014-11-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01909193 on ClinicalTrials.gov